Loading...
Loading...
PYPD| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 6,121.0K |
| Operating I/L | -6,121.0K |
| Other Income/Expense | -171.0K |
| Interest Income | 0.0K |
| Pretax | -6,292.0K |
| Income Tax Expense | 2.0K |
| Net Income/Loss | -6,294.0K |
PolyPid Ltd. is a late-stage biopharma company specializing in the development, manufacturing, and commercialization of products based on the polymer-lipid encapsulation matrix (PLEX) platform. The company's lead product candidate, D-PLEX100, is currently in Phase III clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs). PolyPid generates revenue through the sale of its innovative PLEX-based products, which are designed to address unmet medical needs in the prevention of SSIs, providing a potential source of income through commercialization and distribution.
